Rucaparib is a breakthrough medication that has transformed the treatment landscape for ovarian and prostate cancers. As a PARP (poly ADP-ribose polymerase) inhibitor, Rucaparib works by targeting cancer cells with specific genetic mutations, such as BRCA1 and BRCA2, which impair DNA repair mechanisms. By preventing these cells from repairing themselves, Rucaparib induces cell death, slowing disease progression and improving patient outcomes.
For ovarian cancer, Rucaparib is used as maintenance therapy in patients whose cancer has responded to chemotherapy. It has shown significant benefits in extending progression-free survival, giving patients more time with better quality of life. Similarly, in metastatic prostate cancer, particularly in cases with BRCA mutations, Rucaparib offers a promising option for patients who have limited treatment alternatives.
Trusted Supplier and Manufacturer of Rucaparib ensure a consistent supply of this critical drug, adhering to stringent WHO-GMP standards. Their commitment to quality and affordability enables patients worldwide to access this life-saving treatment.
Reply To This Message - 
